As both the aggregation of Aβ/tau and their interaction play crucial roles in different aspects of AD pathologies, development of drugs that can simultaneously inhibit Aβ and tau aggregation by targeting common structural elements, such as the β-sheet, is of significant interest. This evidence concerns the gene MAPT and Alzheimer disease.